What Is Lynparza (Olaparib)? Which Cancers Is It Used to Treat? Authorization and Reimbursement Conditions

1 · WHAT IS OLAPARIB AND HOW DOES IT WORK?

Lynparza is an oral PARP inhibitor containing olaparib. PARP is a family of enzymes that helps cells repair DNA damage. Olaparib inhibits this system and can also cause PARP proteins to become trapped on DNA. The accumulated damage makes it harder for cancer cells to survive, particularly when another DNA repair pathway is also impaired. This approach is called “synthetic lethality.” [1, 2]

The best-known example is BRCA1 or BRCA2 mutations. However, the term “smart drug” does not mean that healthy cells are completely unaffected. Bone marrow suppression and gastrointestinal complaints are therefore possible. Olaparib differs from conventional cytotoxic chemotherapy; it is a potent anticancer treatment.

2 · FDA APPROVAL TIMELINE

3 · CLINICAL DATA: IN WHOM, AND WHAT WAS SHOWN?

Adjuvant treatment aims to reduce the likelihood of recurrence even when no visible disease remains. Maintenance treatment aims to sustain the control achieved by previous treatment. Treatment of metastatic disease aims to shrink the disease or delay its progression. Therefore, saying “olaparib is never used with curative intent” is incorrect: in early breast cancer, it may be part of the overall treatment with curative intent. However, no guarantee of definitive recovery or prolonged survival can be given for every use.

For Which Patient Groups Is It Currently Approved?

The table below summarizes US/FDA uses; authorization in Turkey and SGK conditions are explained separately later. All indications are for adults. The mutation must be demonstrated by an appropriate test, and stage and previous treatments must be assessed. [1, 11]

In early breast cancer, “high risk” is not determined by the BRCA result alone. In OlympiA, criteria included residual invasive disease after neoadjuvant treatment in triple-negative disease; in hormone receptor-positive disease, additional criteria such as a CPS+EG score ≥3 were used. For hormone receptor-positive patients who underwent surgery first, the criterion is at least four positive lymph nodes. We also discuss patient selection in our article on olaparib in early breast cancer. [12, 19]

Results of the Main Randomized Trials

PFS means the time without disease progression or death; OS means overall survival. In maintenance trials, time generally starts at randomization after chemotherapy is completed. The medians below are not personal time estimates for an individual patient.

The data for ovarian maintenance with bevacizumab from PAOLA-1 and for the prostate combination with abiraterone from PROpel answer different treatment questions. The benefit of a combination cannot be calculated by adding it to the monotherapy result; FDA HRD/BRCA requirements apply separately. [1, 15, 20]

4 · 2026 UPDATE: BENEFIT OF ONE YEAR OF TREATMENT EXTENDING BEYOND SIX YEARS

The message for patients is not to take the medicine for longer: the benefit of a planned one-year course of adjuvant treatment may continue after the medicine has been stopped. Because FDA eligibility, authorization in Turkey, and SGK coverage are not identical, these three aspects should be assessed together, especially in HR-positive early breast cancer. Details: the latest long-term follow-up results of OlympiA.

5 · ADMINISTRATION AND DOSE: WHAT DOES IT MEAN FOR THE PATIENT?

The standard starting dose is 300 mg twice daily; a total of 600 mg/day. Two 150 mg tablets are taken each time. For example, a schedule approximately 12 hours apart, such as 08.00 in the morning and 20.00 in the evening, may be established. This is not a dose routinely calculated by body weight or body surface area; there is no special loading dose. [1, 2, 25]

Olaparib does not use a “take for 21 days, then stop for 7 days” schedule as some other oral treatments do. Treatment is generally planned continuously every day. “Maintenance” here does not mean an automatic move to a lower dose. Safety interruptions recommended by the doctor are exceptions to this rule.

These special doses are not alternatives for patients to implement themselves. If renal impairment and a drug interaction coexist, a dose cannot be calculated by combining rows of the table. [1, 2, 25]

How Long Is It Used, and When Is It Started?

The timing of radiotherapy, endocrine therapy, abiraterone, steroids, or bevacizumab is planned separately. In early hormone receptor-positive breast cancer, endocrine therapy is generally continued. In prostate cancer, testosterone-suppressing treatment is not stopped unless surgical castration has been performed. [1, 2, 4, 9]

Daily Use: Missed Doses, Vomiting, Food, and Storage

A phone alarm and a brief check mark after each dose may reduce missed doses. When the dose changes, keep remaining tablets of different strengths separate at home; ask for written instructions stating how many 100 mg/150 mg tablets to take in the morning and evening on the new prescription. [3, 10, 11, 16]

6 · RESISTANCE MECHANISMS AND TREATMENT SEQUENCING

When progression occurs, assessment considers where and how quickly the disease is progressing, previous treatments, current blood results, and, if necessary, new tissue/liquid biopsy information. Repeat molecular testing is not mandatory for every patient; what matters is the likelihood that the test will change the next treatment. Switching to another PARP inhibitor cannot be assumed to work in every case.

7 · SIDE EFFECTS, MONITORING, AND PATIENT EDUCATION

Side-effect rates vary with cancer type, previous chemotherapies, treatment duration, and concomitant medicines. “All grades” includes mild events; “grade 3–4” indicates severe or potentially life-threatening events. The grade 3–4 rate in trials is the percentage of all patients in the relevant treatment arm, not of patients who experienced that side effect.

For example, in OlympiA, nausea of some grade was reported in approximately 57 out of every 100 patients, whereas severe nausea occurred in fewer than 1 patient. Although anemia was less common, severe anemia was reported at 9%; therefore, monitoring symptoms alone is insufficient, and a complete blood count is needed. In the same trial, leukopenia was 17% for all grades and 3% for grade 3–4. [12]

This table is not a direct comparison of superiority or safety between trials. The PROpel safety population does not consist solely of the BRCA-mutated subgroup. “Clinical anemia” and any laboratory decline in hemoglobin are not the same endpoint; their percentages should not be used interchangeably. A single discontinuation percentage does not represent all uses. [1, 12, 13]

What Does the Grade of a Side Effect Mean, and What Is Done?

These explanations are simplified descriptions of clinical grading; patients do not have to establish their own exact CTCAE grade at home. Grade 5 means death related to a side effect; it is not included in the grade 3–4 columns above. A complaint appearing “mild” does not justify waiting in the case of fever or new shortness of breath. [8, 12]

Nausea and Vomiting

Eating small, frequent meals, reducing strongly smelling or very fatty foods, and taking the medicine with food may help. Antinausea treatment may be needed, especially in the first weeks; there is no rule that “no patient needs premedication.” Use the antinausea medicine prescribed by the physician at the recommended time. Report persistent vomiting, dizziness, or an inability to take fluids without delay. [9, 10]

Fatigue and Anemia

Fatigue may not be due to the medicine alone; anemia, infection, malnutrition, and disease activity are also investigated. Maintaining activity at a tolerated level and taking rest breaks may help. If hemoglobin is low, causes such as bleeding or iron/B12/folate deficiency are assessed; transfusion and dose adjustment are used when needed. Not all anemia is iron deficiency; do not start iron on your own. Shortness of breath at rest, chest pain, or fainting is an emergency.

Neutropenia, Low Platelets, and Infection

Low neutrophil counts may develop without symptoms. Immediately report a fever of 38°C or higher, chills, or rapidly worsening general condition even without fever. Low platelets may cause new bruising, nose/gum bleeding, or blood in urine or stool. Do not start or stop medicines such as blood thinners, aspirin, or ibuprofen on your own; show your medicine list to the team. [8, 10]

Diarrhea

Record the number of bowel movements compared with your own normal pattern; replace losses unless you have a fluid restriction. Use medicines prescribed for diarrhea during cancer treatment as directed. Contact the team the same day if you have four or more watery stools per day above normal, diarrhea that wakes you at night, dizziness, fever, bleeding, or reduced urination. For severe diarrhea, do not simply take an antidiarrheal and wait. [8, 10]

Less Common but Important Risks: When Should You Act Quickly?

Pneumonitis: approximately 1% in the pooled assessment in the FDA label; fatal cases have been reported. If suspected, the physician interrupts olaparib and investigates; if confirmed, the medicine is permanently discontinued. Venous thromboembolism: requires particular attention in prostate cancer trials. Drug-induced liver injury: is also listed as a warning in the current US label; ALT, AST, and bilirubin are monitored at baseline and during treatment. [1, 11]

Is the MDS/AML Risk 8–9% for Everyone?

No. Among patients treated for appropriate indications in the FDA label, 26 of 2,219 patients, approximately 1.2%, were reported to have MDS/AML. In the heavily pretreated recurrent ovarian cancer group, the SOLO2 rate was 8%in the olaparib arm and 4% in the placebo arm. In contrast, at the 6.1-year follow-up of OlympiA, rates were reported as 0.4% and 0.7%. The patient groups, previous DNA-damaging treatments, and follow-up durations differ; these rates cannot be combined into a single personal risk calculation. [1, 12]

The Link Between PARP Inhibitors and Secondary Leukemia is an important monitoring issue; not every decrease in blood counts means leukemia. Prolonged low blood counts may require an interruption and weekly complete blood counts. If blood counts fail to recover to grade 1 or below within four weeks after interruption, hematology assessment and, if necessary, bone marrow and cytogenetic examination are performed. If MDS/AML is confirmed, olaparib is discontinued. [1, 19]

Which Checks Are Needed Before and During Treatment?

Ordering regular PET/CT or tumor markers such as CA 15-3 for every patient taking olaparib is not an appropriate general rule. Routine metastatic screening in asymptomatic early breast cancer is not the same as response monitoring in metastatic disease. Potassium, blood pressure, and liver monitoring in patients receiving abiraterone; and blood pressure, urine protein, and bleeding risk with bevacizumab, are assessed separately. [1, 2, 9]

Drug and Food Interactions: Be Sure to Tell the Team

Olaparib is metabolized through the CYP3A system. Products such as certain antifungals, clarithromycin, and medicines containing ritonavir may increase its level; products such as rifampicin, carbamazepine, phenytoin, and St. John's wort may reduce its effect. Before starting a new antibiotic, antiviral, or herbal product, the oncology team or pharmacist must check for interactions. [1, 2]

Avoid grapefruit and its juice, and bitter/Seville orange products. Marmalade ingredients also matter. Our article on food–drug interactions provides general information; specific restrictions for olaparib should be assessed according to the product information. There is no need to eliminate all fruit or entire food groups without evidence. [3, 11]

[3, 10, 11]

8 · AUTHORIZATION, REIMBURSEMENT, AND COST IN TURKEY

The first authorization date in Turkey for Lynparza 150 mg tablets is 21 November 2018, with authorization number 2018/638. This update is based on the SmPC dated 6 February 2024 accessed through AstraZeneca Turkey's product page. The document date and this article's update date are not the same. The authorization holder is AstraZeneca. [2]

The FDA Approval of the Olaparib–Abiraterone Combination is also discussed in a separate article. An indication in a product document does not mean it is the best treatment sequence for every patient or that SGK will reimburse it. [2, 20]

Under Which Conditions Does SGK Provide Coverage?

The SUT provision accessed, 4.2.14.C/3-mmm, defines four reimbursement areas. The summary below is based on the official amendment dated 2 November 2024 and a transcription of the text containing the same conditions on the access date. At prescribing, the current SUT, EK-4/A, report, and MEDULA eligibility must be verified together. “The medicine is on the list” does not mean it is reimbursed for every cancer. [4, 5]

The same provision restricts reimbursement for repeat PARP inhibitor use in the metastatic setting in a patient who used a PARP inhibitor in early-stage disease. This is a reimbursement rule; it is not a universal scientific conclusion about all future clinical trials.

It is important for the application file to clearly state pathology, the genetic report and variant class, previous medicines, platinum completion date, response/progression dates, and performance status. When faced with the price, clarify the prescription and reimbursement conditions with the team before reducing the medicine on your own.

Lynparza Price: One Box and 28 Days of Treatment Are Not the Same

In an access check on 8 September 2026, two drug price databases show the same retail amount for 150 mg/56 tablets: 68,473.97 TL. One source gives the price's effective date as 1 April 2026. These are publicly available price records, not a quote directly confirming TİTCK's official price file for that day and pharmacy authorization. [6, 7]

Information That May Be Useful to Bring to an Appointment

1. Dose: The strength and number of tablets taken in the morning/evening, and the date of the last change.
2. Symptom diary: Fever, vomiting, bowel movement count, fluid intake, fatigue, and onset of shortness of breath.
3. Complete medicine list: Prescription medicines, painkillers, herbal products, and vitamins.
4. Latest tests: Complete blood count, kidney and liver results; genetic report and treatment dates if needed.
5. Medicine stock: Numbers of 100 mg and 150 mg tablets remaining at home, and when the report/prescription needs renewal.

Success with olaparib treatment depends not only on selecting an appropriate biological target but also on recognizing side effects early and sustaining treatment. Before starting, obtain written clarification of the prescribed tablet strength, total daily dose, intended treatment duration, and the unit to contact in an emergency.

Sources and Currency Note

Sources accessed: 8 September 2026. Clinical evidence, FDA scope, Turkish product information, SUT, and public price records were assessed separately. Clinical trial results are presented with their own patient groups and analysis periods.

1. Lynparza US prescribing information and patient guide. DailyMed; revision July 2025, accessed 8 September 2026.
2. AstraZeneca Turkey. Lynparza 150 mg Summary of Product Characteristics; document dated 6 February 2024, accessed from the company's current product page.
3. AstraZeneca Turkey. Lynparza 150 mg Patient Information Leaflet.
4. SGK. SUT amendment dated 2 November 2024, article 15(f), olaparib 4.2.14.C/3-mmm. SGK copy of the Official Gazette document.
5. SUT 4.2.14.C/3-mmm, Olaparib. Current text transcription; accessed 8 September 2026. Compared with the official document.
6. İlaç Rehberi. Price list for Lynparza 150 mg/56 tablets and 100 mg/56 tablets; list headed 31 August 2026.
7. İlaç Fiyatı. Lynparza 150 mg/56 tablets, barcode 8699786092921; record showing a price effective date of 1 April 2026.
8. eviQ. Advanced, metastatic or recurrent olaparib, protocol 3737.
9. eviQ. Breast adjuvant olaparib, protocol 4061.
10. Cancer Research UK. Olaparib (Lynparza): patient information.
11. Lynparza official patient website. Use, interactions, contraception, and safety.
12. Lynparza HCP. OlympiA safety results; the initial analysis and 6.1-year follow-up are presented separately.
13. Lynparza HCP. SOLO1 safety and tolerability results.
14. Garber JE et al. Sustained benefit of adjuvant olaparib… OlympiA phase III trial. Annals of Oncology, 2026. DOI: 10.1016/j.annonc.2026.08.002.
15. Arora S et al. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for Maintenance Treatment of Patients with Advanced Ovarian Cancer.
16. FDA. 2017 olaparib tablet application: multidisciplinary review report.
17. AstraZeneca. FDA approval in metastatic breast cancer, 12 January 2018.
18. Merck/MSD. FDA maintenance approval in metastatic pancreatic cancer, 30 December 2019.
19. Merck/MSD. FDA adjuvant approval in high-risk early breast cancer, 11 March 2022.
20. FDA. D.I.S.C.O. olaparib–abiraterone approval summary; approval date 31 May 2023.
21. AstraZeneca/MSD. September 2023 healthcare professional letter: BRCA requirement for recurrent ovarian maintenance.
22. FDA / Federal Register. Withdrawal of the olaparib capsule application; 26 March 2024.
23. FDA / Regulations.gov. Withdrawal of advanced ovarian cancer treatment indications, 26 March 2024.
24. SGO. Changes in ovarian cancer FDA indications for PARP inhibitors; historical statement dated December 2022.
25. Lynparza HCP. Dosing and administration in breast cancer.
26. Banerjee S et al. SOLO1/GOG-3004: five-year follow-up. Lancet Oncology, 2021.
27. Robson M et al. OlympiAD: olaparib in metastatic breast cancer. NEJM, 2017.
28. de Bono J et al. PROfound: olaparib in metastatic castration-resistant prostate cancer. NEJM, 2020.
29. Kindler HL et al. POLO: final overall survival analysis. JCO, 2022.
30. Robson ME et al. OlympiAD: final overall survival and tolerability results. Annals of Oncology, 2019.
31. Waks AG et al. Mechanisms of PARP inhibitor/platinum resistance in BRCA1/2-associated breast cancer. Annals of Oncology, 2020.
32. Golan T et al. POLO: maintenance olaparib in germline BRCA-mutated metastatic pancreatic cancer. NEJM, 2019.